Japan approves Afstyla, CSL Behring's next-gen hemophilia A therapy

Japan’s medicines agency has approved CSL Behring’s next generation hemophilia A therapy Afstyla (lonoctocog alfa).

The therapy, which was developed by Korean firm SK Chemicals, was approved in the USA in April 2016, following on from first-to-market treatments of this type, developed by Bioverativ and Swedish Orphan Biovitrum.

These extended half-life infusions reduce the number of injections required to achieve effective bleed prevention.

CSL is supporting its applications with data from the AFFINITY trial program.